Originally published 2021-11-28.
On 26 November 2021, the same day the World Health Organization named the new Omicron variant a variant of concern, US President Joe Biden urged members of the World Trade Organization (WTO) to waive intellectual property protections on Covid-19 vaccines so they could be made around the world. The WTO meeting he was addressing was postponed because of Omicron, and a narrower agreement was finally reached in June 2022.
This page explains what Biden asked for, why a patent waiver was so contested, what was happening with Omicron at the time, and what the WTO eventually agreed.
What Biden called for
In a statement issued at the end of Thanksgiving week, Biden linked the new variant directly to the gap in global vaccination. He said the news should make clearer than ever that the pandemic would not end without vaccinations worldwide.
He then challenged the countries due to gather in Geneva the following week for the WTO's ministerial conference to waive intellectual property protections for Covid vaccines, "so these vaccines can be manufactured globally." He reminded them that his administration had first backed the idea in spring 2021, a major shift in US policy at the time.
Biden also said the United States had donated more vaccine doses abroad than all other countries combined. Some public health experts replied that rich countries, including the US, had still not done nearly enough to close the gap.
What a vaccine patent waiver means
Vaccines are protected by patents and other intellectual property under the WTO's TRIPS Agreement (Trade-Related Aspects of Intellectual Property Rights). Those rights let the companies that developed a product control who can make it, usually for 20 years.
In October 2020, India and South Africa asked the WTO to suspend parts of TRIPS for Covid-19 vaccines, tests, treatments and protective equipment for as long as the pandemic lasted. Their argument was simple: if more manufacturers could legally produce vaccines, poorer countries would not have to wait at the back of the queue while wealthy nations bought up early supplies. Around 100 countries eventually supported the idea.
Opponents, led by the European Union, the United Kingdom and Switzerland, argued that patents were not the main barrier. They pointed to shortages of raw materials, specialised equipment and trained staff, and to the technical know-how needed to make complex mRNA vaccines. They also warned that weakening patents could discourage companies from investing in research for the next pandemic. Switzerland said it was open to compromise but still opposed a full waiver.
Omicron and the travel bans
Scientists in South Africa reported the new variant to the WHO on 24 November 2021. It had also been detected in Botswana, and it carried an unusually large number of mutations, raising fears that it might spread faster than Delta and partly escape the protection offered by vaccines and earlier infection.
Many countries reacted with travel bans. The United States barred entry for most non-US travellers from eight southern African countries: South Africa, Botswana, Zimbabwe, Namibia, Lesotho, Eswatini, Mozambique and Malawi. The UK, the EU and others imposed similar restrictions, and several countries brought back rules on masks and testing.
South Africa's government called the bans unjustified and said the country was being punished for detecting and sharing the variant quickly. The WHO also advised against blanket travel bans. Within days the variant had been found in Europe, Israel, Canada and elsewhere, showing it was already spreading widely. Early anecdotal reports from South African doctors described mostly mild illness, but experts stressed it was too soon to judge severity.
What we later learned about Omicron
Omicron did spread faster than any earlier variant and caused huge waves of infection worldwide in the winter of 2021 to 2022. Two vaccine doses gave much less protection against infection than they had against Delta, but a booster dose restored strong protection against severe illness and hospitalisation.
Studies found that, for an individual, Omicron was on average less likely to cause severe disease than Delta. Because so many people caught it at once, though, it still filled hospitals in many places and caused many deaths, particularly among older and unvaccinated people. Anyone with questions about current Covid vaccines or boosters should talk to a doctor.
The WTO decision of June 2022
The ministerial conference planned for 30 November 2021 was called off at short notice because Omicron travel restrictions made it impossible for many delegates to reach Geneva. When ministers finally met in June 2022, they adopted a much narrower decision than India and South Africa had first proposed.
Under the 17 June 2022 decision, eligible developing countries may use patented ingredients and processes needed to make Covid-19 vaccines without the patent holder's consent, and may export those vaccines to other eligible countries. The decision lasts five years. It covers only vaccines; members were given six months to decide whether to extend it to tests and treatments, but no agreement was reached.
Campaign groups said the deal came too late and offered too little, since global vaccine supply had largely caught up by mid-2022. Supporters said it set a useful precedent for future health emergencies.
What the debate taught the world
The vaccine waiver fight showed that patents are only one part of making medicines available to everyone. Factories, supply chains, technology transfer and fair distribution of early doses matter just as much. Efforts since then, such as the WHO-backed mRNA technology hub in South Africa and negotiations on a global pandemic agreement, have tried to address those wider gaps.
For readers, the key lesson is that a political call for a waiver, an international legal decision and the actual flow of doses are three different things, and each can move at a very different pace.
Sources: Al Jazeera, 26 November 2021; Fasken, June 2022; Wikipedia: SARS-CoV-2 Omicron variant.

COMMENTS